CACYBP and cholangiocarcinoma: These findings support CACYBP’s role as a critical oncogenic driver in LUAD, consistent with its oncogenic function in other malignancies, such as liver, prostate, pancreatic, and colon cancers, as well as cholangiocarcinoma [13–15, 29, 30].